Water for ADPKD? Probably, yes

Journal of the American Society of Nephrology

Volumn 17, Issue 8, 2006, Pages 2089-2091

  Torres, Vicente E ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE; OCTREOTIDE; RAPAMYCIN; VASOPRESSIN; VASOPRESSIN RECEPTOR ANTAGONIST;

EDITORIAL; FLUID INTAKE; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTENSION; KIDNEY POLYCYSTIC DISEASE; PRIORITY JOURNAL; URINE VOLUME;

EID: 33746544244     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: 10.1681/ASN.2006060603     Document Type: Editorial

References (34)

1. Dalgaard OZ: Bilateral polycystic disease of the kidneys: A follow-up of two hundred and eighty-four patients and their families. Acta Med Scand 328: 1-255, 1957
2. Martinez-Maldonado M, Yium JJ, Eknoyan G, Suki WN: Adult polycystic kidney disease: Studies of the defect in urine concentration. Kidney Int 2: 107-113, 1972
3. Gabow P, Kaehny W, Johnson AM, Duley IT, Manco-Johnson M, Lezotte DC, Schrier RW: The clinical utility of renal concentrating capacity in polycystic kidney disease. Kidney Int 35: 675-680, 1989
4. Kaariainen H, Koskimies O, Norio R: Dominant and recessive polycystic kidney disease in children: Evaluation of clinical features and laboratory data. Pediatr Nephrol 2: 296-302, 1988
5. Seeman T, Dusek J, Vondrak K, Blahova K, Simkova E, Kreisinger J, Dvorak P, Kyncl M, Hribal Z, Janda J: Renal concentrating capacity is linked to blood pressure in children with autosomal dominant polycystic kidney disease. Physiol Res 53: 629-634, 2004
6. Danielsen H, Pedersen EB, Nielsen AH, Herlevsen P, Kornerup HJ, Posborg V: Expansion of extracellular volume in early polycystic kidney disease. Acta Med Scand 219: 399-405, 1986
7. Michalski A, Grzeszczak W: The effect of hypervolemia on electrolyte level and level of volume regulating hormones in patients with autosomal dominant polycystic kidney disease [in Polish]. Pol Arch Med Wewn 96: 329-343, 1996
8. Gattone VH, Maser RL, Tian C, Rosenberg JM, Branden MG: Developmental expression of urine concentration-associated genes and their altered expression in murine infantile-type polycystic kidney disease. Dev Gen 24: 309-318, 1999
9. Gattone VH, Wang X, Harris PC, Torres VE: Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist. Nat Med 9: 1323-1326, 2003
10. Torres VE, Wang X, Qian Q, Somlo S, Harris PC, Gattone VH: Effective treatment of an orthologous model of autosomal dominant polycystic kidney disease. Nat Med 10: 363-364, 2004
11. Safouh M, Crocker JF, Vernier RL: Experimental cystic disease of the kidney. Sequential, functional, and morphologic studies. Lab Invest 23: 392-400, 1970
12. Carone FA, Ozono S, Samma S, Kanwar YS, Oyasu R: Renal functional changes in experimental cystic disease are tubular in origin. Kidney Int 33: 8-13, 1988
13. Hayashi M, Yamaji Y, Monkawa T, Yoshida T, Tsuganezawa H, Sasamura H, Kitajima W, Sasaki S, Ishibashi K, Maurmo F, Saruta T: Expression and localization of the water channels in human autosomal dominant polycystic kidney disease. Nephron 75: 321-326, 1997
14. Torres VE, Harris PC: Mechanisms of disease: Autosomal dominant and recessive polycystic kidney diseases. Nat Clin Pract Nephrol 2: 40-54, 2006
15. Wang X, Gattone V 2nd, Harris PC, Torres VE: Effectiveness of vasopressin V2 receptor antagonists OPC-31260 and OPC-41061 on polycystic kidney disease development in the PCK rat. J Am Soc Nephrol 16: 846-851, 2005
16. Yamaguchi T, Wallace DP, Magenheimer BS, Hempson SJ, Grantham JJ, Calvet JP: Calcium restriction allows cAMP activation of the B-Raf/ERK pathway, switching cells to a cAMP-dependent growth-stimulated phenotype. J Biol Chem 40419-40430, 2004
17. Yamaguchi T, Hempson SJ, Reif GA, Hedge AM, Wallace DP: Calcium restores a normal proliferation phenotype in human polycystic kidney disease epithelial cells. J Am Soc Nephrol 17: 178-187, 2006
18. Nagao S, Nishii K, Katsuyama M, Kurahashi H, Marunouchi T, Takahashi H, Wallace DP: Increased water intake decreases progression of polycystic kidney disease in the PCK rat. J Am Soc Nephrol 17: 2220-2227, 2006
19. Hebert LA, Greene T, Levey A, Falkenhain ME, Klahr S: High urine volume and low urine osmolality are risk fac-tors for faster progression of renal disease. Am J Kidney Dis 41: 962-971, 2003
20. Cowley AW Jr, Skelton MM, Kurth TM: Effects of long-term vasopressin receptor stimulation on medullary blood flow and arterial pressure. Am J Physiol 275: R1420-R1424, 1998
21. Sauter D, Fernandes S, Goncalves-Mendes N, Boulkroun S, Bankir L, Loffing J, Bouby N: Long-term effects of vasopressin on the subcellular localization of ENaC in the renal collecting system. Kidney Int 69: 1024-1032, 2006
22. Szentivanyi M Jr, Park F, Maeda CY, Cowley AW Jr: Nitric oxide in the renal medulla protects from vasopressin-induced hypertension. Hypertension 35: 740-745, 2000
23. Bankir L, Ahloulay M, Bouby N, Trinh-Trang-Tan MM, Machet F, Lacour B, Jungers P: Is the process of urinary urea concentration responsible for a high glomerular filtration rate? J Am Soc Nephrol 4: 1091-1103, 1993
24. Bouby N, Bachmann S, Bichet D, Bankir L: Effect of water intake on the progression of chronic renal failure in the 5/6 nephrectomized rat. Am J Physiol 258: F973-F979, 1990
25. Bouby N, Hassler C, Bankir L: Contribution of vasopressin to progression of chronic renal failure: Study in Brattleboro rats. Life Sci 65: 991-1004, 1999
26. Bardoux P, Bichet DG, Martin H, Gallois Y, Marre M, Arthus MF, Lonergan M, Ruel N, Bouby N, Bankir L: Vasopressin increases urinary albumin excretion in rats and humans: Involvement of V2 receptors and the renin-angiotensin system. Nephrol Dial Transplant 18: 497-506, 2003
27. Belibi FA, Wallace DP, Yamaguchi T, Christensen M, Reif G, Grantham JJ: The effect of caffeine on renal epithelial cells from patients with autosomal dominant polycystic kidney disease. J Am Soc Nephrol 13: 2723-2729, 2002
28. Popkin BM, Armstrong LE, Bray GM, Caballero B, Frei B, Willett WC: A new proposed guidance system for beverage consumption in the United States. Am J Clin Nutr 83: 529-542, 2006
29. Villanueva CM, Cantor KP, King WD, Jaakkola JJ, Cordier S, Lynch CF, Porru S, Kogevinas M: Total and specific fluid consumption as determinants of bladder cancer risk. Int J Cancer 118: 2040-2047, 2006
30. Ruggenenti P, Remuzzi A, Ondei P, Pasolini G, Antiga L, Ene-lordache B, Remuzzi G, Epstein FH: Safety and efficacy of long-acting somatostatin treatment in autosomal dominant polycystic kidney disease. Kidney Int 68: 206-216, 2005
31. Omori S, Hida M, Fujita H, Takahashi H, Tanimura S, Kohno M, Awazu M: Extracellular signal-regulated kinase inhibition slows disease progression in mice with polycystic kidney disease. J Am Soc Nephrol 17: 1604-1614, 2006
32. Tao Y, Kim J, Schrier RW, Edelstein CL: Rapamycin markedly slows disease progression in a rat model of polycystic kidney disease. J Am Soc Nephrol 16: 46-51, 2005
33. Wahl PR, Serra AL, Le Hir M, Molle KD, Hall MN, Wuthrich RP: Inhibition of mTOR with sirolimus slows disease progression in Han:SPRD rats with autosomal dominant polycystic kidney disease (ADPKD). Nephrol Dial Transplant 21: 598-604, 2006
34. Shillingford JM, Murcia NS, Larson CH, Low SH, Hedgepeth R, Brown N, Flask CA, Novick AC, Goldfarb DA, Kramer-Zucker A, Walz G, Piontek KB, Germino GG, Weimbs T: The mTOR pathway is regulated by polycystin-1, and its inhibition reverses renal cystogenesis in polycystic kidney disease. Proc Natl Acad Sci USA 103: 5466-5471, 2006